Floatz logo

hbi0101 cart

Idiopathic Inflammatory Myopathy (IIM)

Polina StepenskyCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Idiopathic Inflammatory Myopathy (IIM) cohort.

Asset / SponsorPhaseRating
Filgotinib
UMC Utrecht
Phase 2CCC
azd0120
AstraZeneca
Phase 1CC
Autologous Cd19-Bcma Dual-Target Car T-Cell Therapy
Beijing Boren Hospital
Phase 1CC
her2bbζ/cd19t+ t cells
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Early Phase 1C
ct103a cells
Tongji Hospital
Early Phase 1C
Fludarabine
Tongji Hospital
Early Phase 1C
Cyclophosphamide
Tongji Hospital
Early Phase 1C

Same molecule, other indications

hbi0101 cart is also rated in:

plasma cell myelomaDormant
B
Indicative ·
60 / 100
View asset →
AL amyloidosisDormant
CCC
Indicative ·
53 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →